Tagworks Pharmaceuticals
Thomas Harth is a seasoned investment professional currently serving as a Partner at Ysios Capital since March 2022. Harth holds additional positions as a Member of the Board of Directors for Anaconda BioMed, Memo Therapeutics AG, and Tagworks Pharmaceuticals, with experience as a Board Observer for Anjarium Biosciences and Kinaset Therapeutics. Prior experience includes a role as a Senior Associate at Gimv, where contributions to life science investments were significant, including co-leading investments in Anjarium Biosciences and Kinaset Therapeutics. Academic qualifications consist of a Master of Science in Applied Economics - Corporate Finance and a Master of Science in Bio-engineering - Chemistry and Biotechnology, both obtained from Ghent University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Tagworks Pharmaceuticals
1 followers
Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands. Tagworks develops In vivo chemistry to improve the efficacy of cancer therapies and to enable novel approaches in companion diagnostics. The company’s facilities are located at the Radboud University Medical Center in Nijmegen. Founded in 2011, Tagworks is aspin-out of Philips Healthcare, and originates from Philips’ molecular imaging expertise.